基本信息:
- 专利标题： TREATMENT FOR CUTANEOUS T CELL LYMPHOMA
- 专利标题（中）：皮肤T细胞淋巴瘤的治疗
- 申请号：PCT/US2006049525 申请日：2006-12-28
- 公开(公告)号：WO2007079203A2 公开(公告)日：2007-07-12
- 发明人： ROOK ALAIN H , BENOIT BERNICE M , WYSOCKA MARIA , NEWTON SARAH B , MILLER RICHARD L , TOMAI MARK A
- 申请人： 3M INNOVATIVE PROPERTIES CO , UNIV PENNSYLVANIA , ROOK ALAIN H , BENOIT BERNICE M , WYSOCKA MARIA , NEWTON SARAH B , MILLER RICHARD L , TOMAI MARK A
- 专利权人： 3M INNOVATIVE PROPERTIES CO,UNIV PENNSYLVANIA,ROOK ALAIN H,BENOIT BERNICE M,WYSOCKA MARIA,NEWTON SARAH B,MILLER RICHARD L,TOMAI MARK A
- 当前专利权人： 3M INNOVATIVE PROPERTIES CO,UNIV PENNSYLVANIA,ROOK ALAIN H,BENOIT BERNICE M,WYSOCKA MARIA,NEWTON SARAH B,MILLER RICHARD L,TOMAI MARK A
- 优先权： US75447605 2005-12-28
摘要：
The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.
摘要（中）：
本发明提供了治疗患有皮肤T细胞淋巴瘤（CTCL）的患者的方法。 通常，所述方法包括向患者施用有效量的IRM化合物以改善CTCL的至少一种症状或临床征兆。 在一些实施方案中，所述方法还包括向患者施用引发剂量的I型干扰素。 另一方面，本发明提供了增加包括受皮肤T细胞淋巴瘤影响的细胞的细胞群体的细胞介导的免疫应答的方法。 一般而言，所述方法包括使细胞群与有效量的IRM化合物接触以增加细胞群的至少一种细胞介导的免疫活性。 在一些实施方案中，所述方法包括使细胞群与I型干扰素的引发剂量接触。